clinical trial · NCT07887490
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Anfibatide Injection in Healthy Volunteers
Healthy VolunteersRecombinant Anfibatide InjectionPlacebo
brief summary
This is a Phase I, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Anfibatide Injection in healthy adult volunteers. Approximately 36 healthy participants will receive a single intravenous dose of either study drug or matching placebo across sequential dose cohorts. Safety, tolerability, and pharmacokinetic parameters will be assessed following administration.
started
Nov 30, 2026
primary completion
Dec 31, 2027
completion
Feb 15, 2028
last updated
Oct 21, 2026
official title
A Phase I Clinical Study to Evaluate the Tolerability and Pharmacokinetics of Recombinant Anfibatide Injection After Single Administration in Healthy Adult Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol